Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sectra ABCHIX:SECTBS 100 Cash-to-Debt is 23.67 as of Apr. 2026, which is 94% above its 10-year median of 12.20. GuruFocus rates CHIX:SECTBS with a GF Score™ of 100/100 and a GF Value™ of kr316.34 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 844 Medical Devices & Instruments companies, Sectra AB ranks better than 82.11% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Sectra AB's cash to debt ratio for the quarter that ended in Apr. 2026 was 23.67.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Sectra ABcould pay off its debt using the cash in hand for the quarter that ended in Apr. 2026.
The historical rank and industry rank for Sectra AB's Cash-to-Debt or its related term are showing as below:
CHIX:SECTBs'
s Cash-to-Debt Range Over the Past 10 Years
Min: 3.95 Med: 12.2 Max: No Debt
Current: 23.67
During the past 13 years, Sectra AB's highest Cash to Debt Ratio was No Debt. The lowest was 3.95. And the median was 12.20.
CHIX:SECTBs's Cash-to-Debt is ranked better than 82.11% of 844
companies
in the Medical Devices & Instruments industry
Industry Median: 1.63
vs CHIX:SECTBs: 23.67
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Sectra AB Cash-to-Debt Related Terms
Sectra AB Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Sectra AB's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
CHIX:SECTBS vs ABT, SYK, MDT: Cash-to-Debt Comparison
For the Medical Devices subindustry, Sectra AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sectra AB Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sectra AB's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Sectra AB's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sectra AB (CHIX:SECTBS) has a Cash-to-Debt of 23.67 as of Apr. 2026. This is 94% above median its historical median of 12.20. Over the past decade, Sectra AB's Cash-to-Debt has ranged from 3.95 to 10,000.00. According to the industry distribution chart, Sectra AB ranks #151 out of 844 companies in the Medical Devices & Instruments industry, placing it in the top 17.9%.
Is Sectra AB's Cash-to-Debt too high?
Sectra AB's current Cash-to-Debt of 23.67 is 94% above median its 10-year median of 12.20. Over the past 10 years, this metric has ranged from a low of 3.95 to a high of 10,000.00. The Medical Devices & Instruments industry median Cash-to-Debt is 1.63. Sectra AB's value of 23.67 is 1352.1% above this industry median. Based on the distribution chart, Sectra AB ranks #151 out of 844 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sectra AB has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sectra AB's Cash-to-Debt compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Sectra AB ranks #151 out of 844 companies for Cash-to-Debt. This places Sectra AB in the top 18% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 1.63. Sectra AB's value of 23.67 is 1352.1% above this benchmark. Historically, Sectra AB's own Cash-to-Debt has ranged from 3.95 to 10,000.00 over the past decade. While the company's 10-year median is 12.20 vs. the industry median of 1.63, Sectra AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.63, based on 844 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sectra AB's current Cash-to-Debt of 23.67 is 1352.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sectra AB's current Cash-to-Debt is 23.67, which is 94% above median its own 10-year median of 12.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sectra AB stock overvalued right now?
Based on GuruFocus' analysis, Sectra AB (CHIX:SECTBS) is currently considered Modestly Undervalued. The stock's GF Value™ is kr316.34, compared to a current price of kr276.50 — trading 12.6% below its estimated fair value. The current Cash-to-Debt is 23.67, which is 94% above median its 10-year median of 12.20 and 1352.1% above the Medical Devices & Instruments industry median of 1.63. Sectra AB's overall GF Score™ is 100/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Sectra AB (CHIX:SECTBS), the current Cash-to-Debt is 23.67 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sectra AB (CHIX:SECTBS) Overvalued in 2026?
Based on GuruFocus' analysis, Sectra AB stock appears to be undervalued.
The current stock price of kr276.50 is trading 12.6% below its estimated GF Value™ of kr316.34.
GuruFocus considers Sectra AB to be Modestly Undervalued.
Key valuation signals for CHIX:SECTBS:
Cash-to-Debt: 23.67 (94% above median its 10-year median of 12.20)
GF Value™: kr316.34 vs. price of kr276.50 (12.6% below fair value)
Industry Position: 1352.1% above the Medical Devices & Instruments median (#151 of 844)
No single metric tells the full story. See the CHIX:SECTBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sectra AB develops IT solutions and services for storing, viewing, and working with medical images. The operating business segments are Imaging IT Solutions, Secure Communications, Business Innovation, and Other Operations. It generates maximum revenue from the Imaging IT Solutions segment. The company also offers maintenance in the form of support, system monitoring, and consulting services related to integration, system design, data migration, and business development. Geographically, it derives a majority of its revenue from the United States, followed by Sweden, the United Kingdom, the Netherlands, the Rest of Europe, and the Rest of the world.
100GF Score
Get the complete analysis for CHIX:SECTBS
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:SECTBS has been successfully added to your 
